Ionis told investors in July that TRYNGOLZA was “on track” for $100 million to $110 million in 2026 sales. On November 9, it lowered that target to roughly $50 million.

NEW YORK, Nov. 9, 2026 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today cut its full-year TRYNGOLZA product sales guidance by roughly 50%, to approximately $50 million from a previous range of $100 million to $110 million, and IONS shares fell sharply. IONS shareholders who lost money are encouraged to submit their loss information now . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com  or by telephone at (212) 363-7500.

On July 29, 2026, Ionis announced it was “On track to achieve 2026 financial guidance” and that TRYNGOLZA was “demonstrating early sHTG launch momentum.” Now, on November 9, 2026, the Company is blaming lowered 2026 product sales guidance for TRYNGOLZA on more gradual sHTG launch ramps “reflecting early dynamics of establishing a new treatment paradigm.”

TRYNGOLZA had generated $32 million in first-half 2026 sales, including $5 million in the second quarter. Hitting $100 million to $110 million required roughly $68 million to $78 million in the second half. On November 9, 2026, the target became approximately $50 million. Levi & Korsinsky is investigating potential securities law violations on behalf of IONS investors who suffered losses.

If you purchased IONS shares and suffered a loss, contact the firm to review your shareholder rights  or call Joseph E. Levi, Esq. at (212) 363-7500.

Levi & Korsinsky, LLP  | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com

Frequently Asked Questions About the IONS Investigation

Q: Which statements are being investigated as potentially misleading?  A: The investigation concerns whether Ionis Pharmaceuticals, Inc. made materially false or misleading statements regarding its full-year 2026 TRYNGOLZA product sales guidance. This includes the July 9, 2026 reaffirmation of full-year guidance and the July 29, 2026 statements that TRYNGOLZA was “on track” to meet that guidance. When the Company disclosed on November 9, 2026 that it had lowered full-year TRYNGOLZA guidance to approximately $50 million from a range of $100 million to $110 million, the stock price declined sharply.

Q: When did Ionis Pharmaceuticals allegedly mislead investors? A: The investigation concerns statements made before the November 9, 2026 corrective disclosure that allegedly caused investors to purchase IONS securities at inflated prices.

Q: What do IONS investors need to do right now?  A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?  A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my IONS shares — can I still recover losses?  A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought IONS and sold at a loss may still participate in the investigation.

Q: Do I need to go to court or give testimony?  A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

Q: What does it cost me to participate?  A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-pharmaceuticals-investigation-notice-levi–korsinsky-notifies-investors-of-pending-investigation-into-ionis-pharmaceuticals-ions-302933790.html

SOURCE Levi & Korsinsky, LLP